Thalassemia is a genetic disorder related to blood. In this disease, patient's body is not able to produce normal hemoglobin and manufactures a huge number of abnormal red blood cells, which are continuously destroyed. As a result, an individual becomes anemic.
MARKET DYNAMICS
The thalassemia treatment market is witnessing stupendous growth avenues due to significant growth in the number of blood transfusion and chelation therapy treatments. Moreover, increased number of bone marrow transplants, rise in number of spleen surgeries, and increased investments in research and development activities are some of the key factors stimulating the growth of the global thalassemia treatment market.
MARKET SCOPE
The "Thalassemia Treatment Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of thalassemia treatment market with detailed market segmentation by treatment type. The thalassemia treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in thalassemia treatment market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The thalassemia treatment market is segmented on the basis of treatment type. Based on treatment type, the market is segmented as blood transfusion, chelating therapy, bone marrow transplant, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the thalassemia treatment market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The thalassemia treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting thalassemia treatment market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the thalassemia treatment market in these regions.
MARKET PLAYERS
The report covers key developments in the thalassemia treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from thalassemia treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for thalassemia treatment in the global market. Below mentioned is the list of few companies engaged in the thalassemia treatment market.
The report also includes the profiles of key players in thalassemia treatment market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Acceleron Pharma, Inc.
- bluebird bio, Inc.
- Celgene Corporation
- Novartis AG
- Shire plc (Takeda Pharmaceuticals)
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.